Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 2/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.38 |
| ▸ | PDE4A | P27815 | 5/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.38 |
| ▸ | GRM5 | P41594 | 5/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17399991 | 0.84 | BRD4 (0.38) | FFAR1BRD4 | |
| SCHEMBL17417997 | 0.83 | BRD4 (0.37) | FFAR1BRD4 | |
| SCHEMBL17386210 | 0.81 | CYP2C8 (0.36) | CYP2C8FFAR1GRM5 | |
| SCHEMBL17386181 | 0.81 | BRD4 (0.44) | BRD4 | |
| SCHEMBL17386198 | 0.79 | ALK (0.35) | CYP2C8FFAR1GRM5 | |
| SCHEMBL17429653 | 0.77 | TDP1 (0.41) | BRD4 | |
| SCHEMBL17386350 | 0.77 | MAPT (0.44) | BRD4 | |
| SCHEMBL17386058 | 0.76 | CA12 (0.41) | BRD4 | |
| SCHEMBL17385742 | 0.75 | FFAR1 (0.39) | FFAR1BRD4 | |
| SCHEMBL17417986 | 0.75 | FFAR1 (0.53) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643946-B2 | Tricyclic compound and use thereof | SK CHEMICALS CO., LTD. (KR) | 2017-05-09 | — | — | US | disclosed |
| US-9643946-B2 | Tricyclic compound and use thereof | SK CHEMICALS CO., LTD. (KR) | 2017-05-09 | — | — | US | disclosed |
| US-9643946-B2 | Tricyclic compound and use thereof | SK CHEMICALS CO., LTD. (KR) | 2017-05-09 | — | — | US | disclosed |
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK CHEMICALS CO., LTD. (KR) | 2016-01-14 | — | — | US | disclosed |
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK CHEMICALS CO., LTD. (KR) | 2016-01-14 | — | — | US | disclosed |
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK CHEMICALS CO., LTD. (KR) | 2016-01-14 | — | — | US | disclosed |
| EP-2963027-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK Chemicals Co., Ltd. (KR) | 2016-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | GPR65, GPR119, GPR35 | CYP2C8 1023/4885RIPK2 2191/4885FFAR1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.